Fund details
Life sciences-focused early-stage firm investing in discoveries with the potential to prevent, detect, and cure diseases.
Go to profile
Partners related to this fund
Steve Gillis
Managing Director
Dr. Gillis, managing director at Arch Venture Partners, focuses on evaluating new life science technologies and growing Arch's biotechnology portfolio. He is also a director at numerous biotech companies and was a founder of Immunex and Corixa. He has over 300 publications in molecular and tumor immunology.
Investor scope
Investment criteria breakdown.
Investment stages
Seed
Series A
Target regions
USA
Investment ranges
$100K - $500K
$500K - $1M
$1M - $3M
$3M - $10M
Focus areas
Not found
Related unicorns
A glimpse at some of the $1B+ valuation companies backed by this fund.
Investors targeting related sectors
No partner found.
.svg)
